TNF inhibitors for the treatment of retinal disorders
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 6, 2002
Issued Date -
N/A
app pub date -
Sep 19, 2000
filing date -
Feb 24, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method is disclosed for inhibiting the action of TNF for treating conditions of the optic nerve or retina in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue, or for modulating the immune response affecting neuronal tissue of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), CDP571 (a humanized monoclonal anti-TNF-alpha antibody), and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of a human, or for modulating the immune response affecting neuronal tissue of a human.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully